Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary-Reference-Cited by-同舟云学术

Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary

Published:2015-06 Issue:6 Volume:26 Page:1058-1068
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Morrison V.A.,Hamlin P.,Soubeyran P.,Stauder R.,Wadhwa P.,Aapro M.,Lichtman S.M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/6/1058/5244422/mdv018.pdf

Reference127 articles.

1. Hydroxy-daunomycin (adriamycin) combination chemotherapy in malignant lymphoma;McKelvey;Cancer,1976

2. Malignant lymphomas in the elderly;O'Reilly;Clin Geriatr Med,1997

3. Treatment considerations in the elderly patient with lymphoma;Connors;Hematol Oncol Clin North Am,1997

4. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma;Fisher;N Engl J Med,1993

5. Non-Hodgkin's lymphoma in the older person: a review;Ballester;J Am Geriatr Soc,1993

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis;Leukemia & Lymphoma;2024-07-31

2. A Case of Diffuse Large B Cell Lymphoma With Rapidly Developing Abdominal Distension As the Only First Clinical Presentation;Cureus;2024-07-18

3. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy;American Journal of Hematology;2024-03-19

4. Hematologic Malignancies;Geriatric Medicine;2024

5. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma;Clinical Cancer Research;2023-03-31